Cargando…
A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score
Introduction: Platinum-based chemotherapy is the first-line treatment strategy for ovarian cancer patients. The dismal prognosis of ovarian cancer was shown to be stringently associated with the heterogeneity of tumor cells in response to this therapy, therefore understanding platinum sensitivity in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508345/ https://www.ncbi.nlm.nih.gov/pubmed/37732324 http://dx.doi.org/10.3389/fgene.2023.1240068 |
_version_ | 1785107516942712832 |
---|---|
author | Yang, Fan Wei, Wei Li, Ganghua Lan, Qiongyu Liu, Xiwei Gao, Lin Zhang, Chao Fan, Jiangtao Li, Jundong |
author_facet | Yang, Fan Wei, Wei Li, Ganghua Lan, Qiongyu Liu, Xiwei Gao, Lin Zhang, Chao Fan, Jiangtao Li, Jundong |
author_sort | Yang, Fan |
collection | PubMed |
description | Introduction: Platinum-based chemotherapy is the first-line treatment strategy for ovarian cancer patients. The dismal prognosis of ovarian cancer was shown to be stringently associated with the heterogeneity of tumor cells in response to this therapy, therefore understanding platinum sensitivity in ovarian cancer would be helpful for improving patients’ quality of life and clinical outcomes. HRDetect, utilized to characterize patients’ homologous recombination repair deficiency, was used to predict patients’ response to platinum-based chemotherapy. However, whether each of the single features contributing to HRD score is associated with platinum sensitivity remains elusive. Methods: We analyzed the whole-exome sequencing data of 196 patients who received platinum-based chemotherapy from the TCGA database. Genetic features were determined individually to see if they could indicate patients’ response to platinum-based chemotherapy and prognosis, then integrated into a Pt-score employing LASSO regression model to assess its predictive performance. Results and discussion: Multiple genetic features, including bi-allelic inactivation of BRCA1/2 genes and genes involved in HR pathway, multiple somatic mutations in genes involved in DNA damage repair (DDR), and previously reported HRD-related features, were found to be stringently associated with platinum sensitivity and improved prognosis. Higher contributions of mutational signature SBS39 or ID6 predicted improved overall survival. Besides, arm-level loss of heterozygosity (LOH) of either chr4p or chr5q predicted significantly better disease-free survival. Notably, some of these features were found independent of HRD. And SBS3, an HRD-related feature, was found irrelevant to platinum sensitivity. Integrated all candidate markers using the LASSO model to yield a Pt-score, which showed better predictive ability compared to HRDetect in determining platinum sensitivity and predicting patients’ prognosis, and this performance was validated in an independent cohort. The outcomes of our study will be instrumental in devising effective strategies for treating ovarian cancer with platinum-based chemotherapy. |
format | Online Article Text |
id | pubmed-10508345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105083452023-09-20 A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score Yang, Fan Wei, Wei Li, Ganghua Lan, Qiongyu Liu, Xiwei Gao, Lin Zhang, Chao Fan, Jiangtao Li, Jundong Front Genet Genetics Introduction: Platinum-based chemotherapy is the first-line treatment strategy for ovarian cancer patients. The dismal prognosis of ovarian cancer was shown to be stringently associated with the heterogeneity of tumor cells in response to this therapy, therefore understanding platinum sensitivity in ovarian cancer would be helpful for improving patients’ quality of life and clinical outcomes. HRDetect, utilized to characterize patients’ homologous recombination repair deficiency, was used to predict patients’ response to platinum-based chemotherapy. However, whether each of the single features contributing to HRD score is associated with platinum sensitivity remains elusive. Methods: We analyzed the whole-exome sequencing data of 196 patients who received platinum-based chemotherapy from the TCGA database. Genetic features were determined individually to see if they could indicate patients’ response to platinum-based chemotherapy and prognosis, then integrated into a Pt-score employing LASSO regression model to assess its predictive performance. Results and discussion: Multiple genetic features, including bi-allelic inactivation of BRCA1/2 genes and genes involved in HR pathway, multiple somatic mutations in genes involved in DNA damage repair (DDR), and previously reported HRD-related features, were found to be stringently associated with platinum sensitivity and improved prognosis. Higher contributions of mutational signature SBS39 or ID6 predicted improved overall survival. Besides, arm-level loss of heterozygosity (LOH) of either chr4p or chr5q predicted significantly better disease-free survival. Notably, some of these features were found independent of HRD. And SBS3, an HRD-related feature, was found irrelevant to platinum sensitivity. Integrated all candidate markers using the LASSO model to yield a Pt-score, which showed better predictive ability compared to HRDetect in determining platinum sensitivity and predicting patients’ prognosis, and this performance was validated in an independent cohort. The outcomes of our study will be instrumental in devising effective strategies for treating ovarian cancer with platinum-based chemotherapy. Frontiers Media S.A. 2023-09-05 /pmc/articles/PMC10508345/ /pubmed/37732324 http://dx.doi.org/10.3389/fgene.2023.1240068 Text en Copyright © 2023 Yang, Wei, Li, Lan, Liu, Gao, Zhang, Fan and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Yang, Fan Wei, Wei Li, Ganghua Lan, Qiongyu Liu, Xiwei Gao, Lin Zhang, Chao Fan, Jiangtao Li, Jundong A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score |
title | A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score |
title_full | A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score |
title_fullStr | A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score |
title_full_unstemmed | A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score |
title_short | A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score |
title_sort | novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than hrd score |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508345/ https://www.ncbi.nlm.nih.gov/pubmed/37732324 http://dx.doi.org/10.3389/fgene.2023.1240068 |
work_keys_str_mv | AT yangfan anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT weiwei anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT liganghua anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT lanqiongyu anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT liuxiwei anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT gaolin anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT zhangchao anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT fanjiangtao anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT lijundong anovelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT yangfan novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT weiwei novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT liganghua novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT lanqiongyu novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT liuxiwei novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT gaolin novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT zhangchao novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT fanjiangtao novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore AT lijundong novelmarkerintegratingmultiplegeneticalterationsbetterpredictsplatinumsensitivityinovariancancerthanhrdscore |